SPDR S&P Biotech ETF (NYSEARCA:XBI) Shares Sold by Chatham Capital Group Inc.

Chatham Capital Group Inc. trimmed its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 20.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,078 shares of the exchange traded fund’s stock after selling 1,300 shares during the quarter. Chatham Capital Group Inc.’s holdings in SPDR S&P Biotech ETF were worth $457,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in XBI. Healthcare of Ontario Pension Plan Trust Fund lifted its position in SPDR S&P Biotech ETF by 198.6% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 9,229,000 shares of the exchange traded fund’s stock worth $911,825,000 after acquiring an additional 6,138,000 shares during the period. Clal Insurance Enterprises Holdings Ltd acquired a new stake in shares of SPDR S&P Biotech ETF in the 3rd quarter valued at approximately $141,284,000. Proficio Capital Partners LLC lifted its holdings in shares of SPDR S&P Biotech ETF by 16,156.1% in the 4th quarter. Proficio Capital Partners LLC now owns 917,329 shares of the exchange traded fund’s stock valued at $82,615,000 after buying an additional 911,686 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of SPDR S&P Biotech ETF in the 4th quarter valued at approximately $55,529,000. Finally, Assetmark Inc. lifted its holdings in shares of SPDR S&P Biotech ETF by 72,653.0% in the 3rd quarter. Assetmark Inc. now owns 589,299 shares of the exchange traded fund’s stock valued at $58,223,000 after buying an additional 588,489 shares during the period.

SPDR S&P Biotech ETF Price Performance

XBI opened at $87.06 on Friday. The business has a 50 day simple moving average of $90.68 and a 200-day simple moving average of $95.52. The stock has a market capitalization of $5.74 billion, a P/E ratio of 11.47 and a beta of 0.93. SPDR S&P Biotech ETF has a 12 month low of $81.14 and a 12 month high of $105.47.

SPDR S&P Biotech ETF Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.